Both prostratin and ingenol decreased ECM mineralization in OM (−2.9 fold, p = 0.001 and −5.6 fold, p = 0.005, respectively) (Figure 4C and Supplementary Figure 6A), which was abolished by the PKC inhibitor Go6983 (Figure 4D and Supplementary Figure 6B), supporting the predicted effect from the in silico analysis. This evidence concerns the gene PRRT2 and ocular melanoma.